Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future

References

• Rivera D, Ferrajoli A. Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr Oncol Rep. 2022;24(8):1003–1014. doi:10.1007/s11912-022-01261-9
   PubMed Web of Science ®Google Scholar
• Collins J 4th, Stump SE, Heiling H, et al. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2022;63(8):1823–1830. doi: 10.1080/10428194.2022.2045597
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615. doi: 10.1182/blood-2016-12-737346
   PubMed Web of Science ®Google Scholar
• Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncology. 2016;21(3):354–376. doi: 10.1634/theoncologist.2015-0405
   Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. chronic lymphocytic leukemia/small lymphocytic lymphoma: version 3.2023. National Comprehensive Cancer Network; 2023 Sep 15. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf
   Google Scholar
• Imbruvica (ibrutinib). Package insert. Sunnyvale, CA: Janssen Biotech, Inc and Pharmacyclics; 2015.
   Google Scholar
• Jaypirca (pirtobrutinib). Package insert. Indianapolis, IN: Eli Lilly; 2023.
   Google Scholar
• Venclexta (venetoclax). Package insert. South San Francisco, CA: Genentech; 2016.
   Google Scholar
• Gazyva(Obintuzumab). Package insert. South San Francisco, CA: Genentech; 2013.
   Google Scholar
• Zydelig (idelalisib). Package insert. Foster City, CA: Gilead; 2014.
   Google Scholar
• Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207.
   PubMed Web of Science ®Google Scholar
• Muluneh B, Schneider M, Faso A, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14(6):e324–e334. doi: 10.1200/JOP.17.00039
   PubMed Web of Science ®Google Scholar
• Farris KB, Cadwallader T, Farley J, et al. Implementation of a model integrating primary and oncology pharmacists’ care for patients taking oral anticancer agents (OAA). Explor Res Clin Soc Pharm. 2022;7:100163. doi:10.1016/j.rcsop.2022.100163
   PubMedGoogle Scholar
• Hall AE, Paul C, Bryant J, et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2016;97:247–262. doi: 10.1016/j.critrevonc.2015.08.025
   PubMed Web of Science ®Google Scholar
• Iacorossi L, Gambalunga F, Fabi A, et al. Adherence to oral administration of endocrine treatment in patients with breast cancer: a qualitative study. Cancer Nurs. 2018;41(1):E57–E63. doi: 10.1097/NCC.0000000000000452
   PubMed Web of Science ®Google Scholar
• Oncology Pharmacy Education Network. Care coordination: the role of pharmacy to help manage patients with cancer on oral oncolytics. Association Of Community Cancer Centers (ACCC). 2021;36(5):70–74.
   Google Scholar
• Almodóvar AS, Ross E, Nahata MC, et al. Social needs of dual-enrolled medicare-medicaid patients with medication nonadherence in a telehealth medication therapy management program. J Manag Care Spec Pharm. 2023;29(2):210–215. doi:10.18553/jmcp.2023.29.2.210
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. CLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi: 10.1182/blood-2017-09-806398
   PubMed Web of Science ®Google Scholar
• Anders B, Shillingburg A, Newton M. Oral antineoplastic agents: assessing the delay in care. Chemother Res Pract. 2015;2015:1–4. doi: 10.1155/2015/512016
   Google Scholar
• Mackler E, Petersen L, Severson J. Implementing a method for evaluating patient-reported outcomes associated with oral oncolytic therapy. J Oncol Pract. 2017;13(4):e395–e400. doi: 10.1200/JOP.2016.018390
   PubMed Web of Science ®Google Scholar
• Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37(1):3–14. doi: 10.1002/hon.2540
   PubMed Web of Science ®Google Scholar
• Rogala BG, Charpentier MM, Nguyen MK, et al. Oral anticancer therapy: management of drug interactions. J Oncol Pract. 2019;15(2):81–90. doi:10.1200/JOP.18.00483
   PubMed Web of Science ®Google Scholar
• Brukinsa (zanubrutinib). Package insert. BeiGene USA: Inc.; 2019.
   Google Scholar
• Calquence (acalabrutinib). Package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022.
   Google Scholar
• Copiktra (duvelisib). Package insert. Las Vegas, NV: Secura Bio; 2018.
   Google Scholar
• Billioux A, DPhil MD, Verlander K, et al. Standardized screening for health-related social needs in clinical settings: the accountable health communities screening tool. Nat Acad Med Persp. 2017;7(5):1–9. https://nam.edu/wpcontent/uploads/2017/05/Standardized-Screening-for-Health-Related-Social-Needs-in-Clinical-Settings.pdf
   Google Scholar
• Lexicomp Online. Pediatric and neonatal lexi-drugs online. Waltham (MA): UpToDate, Inc.; 2021 Jul 30 [cited 2024 Jan 24]. Available from: https://online.lexi.com
   Google Scholar
• Muluneh B, Deal A, Alexander MD, et al. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. J Oncol Pharm Pract. 2018;24(2):98–109. doi: 10.1177/1078155216679026
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wickersham KE, Zhang X, et al. Side effects, self-management activities, and adherence to oral anticancer agents. Patient Prefer Adherence. 2019;13:2243–2252. doi: 10.2147/PPA.S224496
   PubMed Web of Science ®Google Scholar
• Parikh SA, Rabe KG, Kay NE, et al. Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014;99(1):140–147. doi: 10.3324/haematol.2013.086066
   PubMed Web of Science ®Google Scholar
• Teregulova DR, Bakirov BA, Akhmadeeva LR. Vliianie affektivnykh i kognitivnykh narusheniĭ na kachestvo zhizni u patsientov s limfoproliferativnymi zabolevaniiami [An impact of affective and cognitive impairment on the quality of life in patients with lymphoproliferative diseases]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(4):5–8. [ Russian]. doi: 10.17116/jnevro20191190415
   PubMedGoogle Scholar
• Chen Y, Chen Z, Jin H, et al. Associations of financial toxicity with symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home: a prospective observational study. BMC Cancer. 2023;23(1):140. doi:10.1186/s12885-023-10580-4
   PubMed Web of Science ®Google Scholar
• Yezefski T, Schwemm A, Lentz M, et al. Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. Semin Hematol. 2018;55(4):185–188. doi:10.1053/j.seminhematol.2017.07.004
   PubMed Web of Science ®Google Scholar
• Papadakos JK, Hasan SM, Barnsley J, et al. Health literacy and cancer self-management behaviors: a scoping review. Cancer. 2018;124(21):4202–4210. doi: 10.1002/cncr.31733
   PubMed Web of Science ®Google Scholar